View recently published Stock News reports from independent reports and journalists. (2022-09-12 | TSX:TH) Theratechnologies TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (SORT1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Fri, 17 Apr 2015 15:08:33 GMT ~ Supreme Court of Canada rules in favour of Theratechnologies. MONTREAL, Oct. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. By continuing to use our service, you agree to our use of cookies. 2. The money will be used to grow the company’s FDA-approved drugs, Egrifta SV (tesamorelin), used for the reduction of excess. TORONTO, May 19, 2023 /CNW/ - This press release is being disseminated as required by. Story. It engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). (THTX) stock. Cookies are used to offer you a better browsing experience and to analyze our traffic. Stockhouse. We currently market prescription products for people with HIV in the United States. Theratechnologies Draws Down on US$20 Million Second Tranche Under its Term Loan Facility With Affiliates of Marathon Asset Management. This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. Biopharmaceutical company Theratechnologies Inc. 49%) At close: 04:00PM EST 1. Investor Relations. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 ir@theratech. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) today announced the publication of a preclinical study demonstrating the in vitro and in vivo efficacy of TH1902, an investigational sortilin (SORT1)-targeted peptide-drug conjugate, in inhibiting ovarian cancer and triple-negative breast cancer (TNBC. com uses cookies on this site. (THTX) Stock Price, Quote & News - Stock Analysis -20. Stockhouse. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 89 $2. The Montreal-based biopharmaceutical company's consolidated net revenues for fourth quarter 2020 are expected to be between US$18. Stockhouse. Clinical-stage pharmaceutical company Theralase Technologies Inc. , a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. Theratechnologies Inc. View real-time stock prices and stock quotes for a full financial overview. Free cash flow. com uses cookies on this site. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that new data featuring its investigational sortilin 1 (SORT1)-targeting peptide-drug conjugate technology will be presented in three posters at the American. Cookies are used to offer you a better browsing experience and to analyze our traffic. 19, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. stockhouse. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 00. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies,. com. was a. 5000 +0. Early Warning Report Issued Pursuant to National Instrument 62-103 - Acquisition of Securities of Theratechnologies Inc. com uses cookies on this site. is an employee of TaiMed Biologics USA, Inc. European Headquarters. 54% and a negative trailing twelve-month return on equity of. Further information about Theratechnologies is available on the Company’s website at on SEDAR+ at and. com uses cookies on this site. Theratechnologies presented the pre-clinical and clinical data gathered thus far to the SAC, which made recommendations to modify the frequency of administration, selection of tumor types and. (2022-10-03 | TSX:TH) Theratechnologies' Trogarzo® Approved by FDA for 30-Second Intravenous (IV) Push, Simplifying HIV Treatment for Heavily Treatment-Experienced Population. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . Cookies are used to offer you a better browsing experience and to analyze our traffic. com. By continuing to use our service, you agree to our use of cookies. Theratechnologies layoffs. com uses cookies on this site. (“Theratechnologies” or the “Company”) (TSX: TH) today announced that it has applied to list its common shares on NASDAQ. 39 50-Day Range $0. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that President and CEO, Paul Lévesque has issued an open letter to shareholders. 9 million and US$19. MONTREAL, Jan. Cookies are used to offer you a better browsing experience and to analyze our traffic. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ¨ Form 40-F xToronto, Ontario-- (Newsfile Corp. By continuing to use our service, you agree to our use of cookies. Theratechnologies affirms fiscal 2022 revenue to be in the range of $79 million and $84 million for full fiscal 2022, or growth of the commercial portfolio to be in the range of 13% and 20% as. 25. MONTREAL, Oct. $30. Common Shares (THTX) Stock Price, Quote, News & History | Nasdaq Nasdaq Data Link's products page Investors may trade in the Pre-Market (4:00. 5% workforce reduction. 74M. Amount of cash a business has after it has met its financial obligations such as debt and outstanding payments. 22, 2023 /CNW/ - Northwest Healthcare Properties Real Estate Investment Trust (the "REIT" or "Northwest") (TSX: NWH. L. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. The abstract and poster can be found on Theratechnologies’ website. THERATECHNOLOGIES INC. The Canadian company develops peptide sequences to treat endocrine and metabolic conditions such as growth hormone deficiencies. (TH. 75. Theratechnologies. com. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650 [email protected] (TH) has posted net revenue estimates for fourth quarter and the full fiscal year ending Nov 30, 2020. We also use them to share usage information with our partners. Katana shareholders will. FDA for its IV push form of administration of Trogarzo. Saint-Laurent, Canada. 24 million, 48. (2022-10-26 | TSX:TH) Theratechnologies Reports Data Showing High Expression of Sortilin (SORT1) in Multiple Solid Tumors from Tissue Microarrays. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company will present data from tissue microarrays showing high. Real-time Price Updates for Theratechnologies (TH-T), along with buy or sell indicators, analysis, charts, historical performance, news and more(2018-03-06 | TSX:TH) Theratechnologies Announces FDA Approval of Breakthrough Therapy, Trogarzo™ (ibalizumab-uiyk) Injection, the First HIV-1 Inhibitor and Long-Acting Monoclonal Antibody for Multidrug Resistant HIV-1. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and. There are 102 news items for this page. We also use them to share usage. 7 ( 1D) About THTX In 2022, THTX's revenue was 80. MONTREAL, Oct. 14, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update. 26, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Trogarzo ® is a long-acting, CD4-directed, post-attachment HIV-1 inhibitor. About Us | Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. H. Theratechnologies Inc. 's motion for leave to commence. Cookies are used to offer you a better browsing experience and to analyze our traffic. Stockhouse. S. Theratechnologies Stock (NASDAQ: THTX) stock price, news, charts, stock research, profile. S. Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Revenues have been growing at an average rate of 10. T. M. . Learn why it. By continuing to use our service, you agree to our use of cookies. 69 to $1. Stockhouse. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced publi. Theratechnologies affirms fiscal 2022 revenue to be in the range of $79 million and $84 million for full fiscal 2022, or growth of the commercial portfolio to be in the range of 13% and 20% as compared to the 2021 fiscal year. (THTX) Stock Price, Quote, latest community messages, chart, news and other stock related information. Cookies are used to offer you a better browsing experience and to analyze our traffic. Find more information. Data Link's cloud-based technology platform allows you to search, discover and access data and analytics for seamless integration via cloud APIs. (2023-07-21 | TSX:TH) Theratechnologies Announces the Resignation of One of Its Directors, Mr. Stockhouse. Elif McDonald - Senior Director, Investor Relations. Theratechnologies Inc. 60%. Stockhouse. View real-time stock prices and stock quotes for a full financial overview. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented preclinical data that demonstrate the potential utility of its lead investigational. (2022-02-24 | TSX:TH) Theratechnologies Reports Financial Results for Fiscal 2021 and Provides Business Update. $30. GUD | Complete Knight Therapeutics Inc. 11, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights. Denis Boucher. 01, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. MONTREAL, Sept. . (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results for its second quarter of fiscal 2022 ended May 31 on Thursday, July 14, 2022. (NASDAQ:THTX) Q3 2021 Earnings Call October 13, 2021 8:30 A. Betteryear2. Currency in USD Follow 2W 10W 9M 1. Focused on small-cap companies and sectors. MONTREAL, June 30, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. , a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced further changes to its operations that will see a tapering. MONTREAL, May 09, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and. Headquarters. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the strengthening of its global commercial. Phone Number 15143319691. $44. e. Rosenberg, Reference is made to your letter dated August 16, 2012 regarding the Form 40-F for fiscal year-end November 30, 2011 filed by Theratechnologies Inc. The ADRIQ (Association pour le développement de la recherche et de l’innovation du Québec) rewards Quebec-based companies for leadership and innovation in their respective. A high-level overview of Theratechnologies Inc. TO) Stock Price, News, Quote & History - Yahoo Finance Canada Markets close in 43 mins S&P/TSX 20,125. Theratechnologies Inc. [email protected] Inc: Overview. Stockhouse. 2022 Revenue Guidance Theratechnologies anticipates fiscal 2022 revenue to be in the range of $79 million and $84 million for full fiscal 2022, or growth of the commercial portfolio to be in the. We also use them to share usage. TO) stock quote, history, news and other vital information to help you with your stock trading and investing. ir@theratech. 40%) (As of 11/17/2023 ET) Compare Today's Range $1. The firm offers its product under the brand name of. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. 00 in the next twelve months. CALGARY, AB, May 12, 2022 /PRNewswire/ - Exro Technologies Inc. Stockhouse. We also use them to share usage information with our partners. 16, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 2% to $21. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies (TSX:TH)has indicated that Trogarzo did not meet its primary endpoints in its IM method study. Cookies are used to offer you a better browsing experience and to analyze our traffic. Northwest also announces an update on its. Theratechnologies (THTX) Stock Price, News & Analysis $1. NCU. By continuing to use our. /NOT FOR DISTRIBUTION TO UNITED STATES OF AMERICA WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES OF AMERICA/. We also use them to share usage. 11/05/2020 4:15:02 PM. About TH1902. (Theratechnologies, or the Company (on a consolidated basis)) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on. (2022-05-31 | TSX:TH) Theratechnologies Announces New Head of Investor Relations. 26 +15. MONTREAL, Feb. Join the discussion: Find out what everybody’s saying about this stock on the Theratechnologies Bullboard, and check out the rest of Stockhouse’s stock forums and message boards. . com uses cookies on this site. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Background: Breast and ovarian cancer stem cells (CSC) can contribute to the invasive and chemoresistance phenotype of tumors. THERATECHNOLOGIES INC. The company reported ($0. Theratechnologies, Inc. MONTREAL, July 23, 2021 /CNW Telbec/ - Theratechnologies Inc. com uses cookies on this site. This news release constitutes a “designated news release” for the purposes. Thank you. MONTREAL, Aug. The business had revenue of $27. THTX | Complete Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced it will report financial results and provide a business update for its second. 40%. We currently market prescription products for people with HIV in the United States. (882) posted 3 minutes ago. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced it will report financial results and provide a business update for its second quarter. Sol-Gel Technologies (NASDAQ:SLGL) and Theratechnologies (NASDAQ:THTX) are both small-cap medical companies, but which is the better investment?We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, community ranking, risk,. 40 f102M H1. Stable Share Price: TH is more volatile than 90% of Canadian stocks over the past 3 months, typically moving +/- 25% a week. stock news by MarketWatch. com. - Cash, bonds and money market funds of US$22. Message Board Total Posts: 4. MONTREAL, July 23, 2021 /CNW Telbec/ - Theratechnologies Inc. For investor inquiries: Leah Gibson. MONTREAL, July 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. It’s lead investigational peptide drug conjugate linked to docetaxel, a well-established and well-characterized cytotoxic agent used in the treatment of. Theratechnologies Inc. Further. 1-514-336-7800. MONTREAL, April 08, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TH. 1 Wall Street analysts have set twelve-month price targets for Theratechnologies in the last year. Consensus forecasts updated Jul 21. It is the Company’s proprietary. By continuing to use our service, you agree to our use of cookies. MONTREAL, Oct. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced it will report financial results and provide a business update for its second. (2022-07-27 | TSX:TH) Theratechnologies Announces Closing of Funding of $40 Million Under the Terms of its Credit Agreement. com uses cookies on this site. com uses cookies on this site. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . With the company starting 2023 with 8,725 employees, that’s an 11. ) Clinical-stage pharmaceutical company Theralase Technologies Inc. com uses cookies on this site. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced publi. 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies stated the primary endpoint measured a 90 per cent confidence interval of the IM injection to IV injection (0. This news release constitutes a “designated news release” for the purposes of the. com uses cookies on this site. This is the list of the largest public listed companies in the Drug Manufacturers—Specialty & Generic industry from Canada by market capitalization with links to their reference stock. com uses cookies on this site. Theratechnologies inc. Type: Company - Public (TH) Revenue: $5 to $25 million (USD) Biotech & Pharmaceuticals. S. $109. Share your ideas and get valuable. MONTREAL, Sept. The webinar will also address system-level barriers and present real-world. Montréal, Québec, Canada . Cookies are used to offer you a better browsing experience and to analyze our traffic. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the second quarter and first half of. 4. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. MONTREAL, Oct. US Headquarters. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. If you have HIV, it's important to know the difference. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. com uses cookies on this site. (2021-05-31 | TSX:TH) Theratechnologies Hires Vice President, Human Resources. T. - 2023 Q3 positive adjusted EBITDA to be. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Volatility Over Time: TH's weekly volatility has increased from 16% to 25% over the past year. com uses cookies on this site. Cookies are used to offer you a better browsing experience and to. has received a $100 million binding commitment with respect to a non-dilutive term loan with an affiliate of Marathon Asset Management. TH | September 26, 2023. Theratechnologies last announced its earnings data on September 26th, 2023. By continuing to use our service, you agree to our use of cookies. Theratechnologies, Inc. Vice President, Communications and Corporate Affairs. Theratechnologies inc. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650For the three- and six-month periods ended May 31, 2023, consolidated revenue was $17,549,000 and $37,457,000, compared to $19,268,000 and $37,825,000 for the same periods ended May 31, 2022. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Cookies are used to. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 29(+0. By continuing to use our service, you agree to our use of cookies. July 24 - Heron Therapeutics: Heron is turning to layoffs for the second time in 13 months to cut. By continuing to use our service, you agree to our use of cookies. MONTREAL, Sept. 04) earnings per share (EPS) for the quarter. The company offers EGRIFTA and EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus. By continuing to use our service, you agree to our use of cookies. Herein, we report. 22, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. MONTREAL, Nov. Theratechnologies is leveraging its SORT1+ Technology™ to develop a new class of therapy that targets sortilin (SORT1)-positive cancers by linking anticancer drugs to proprietary peptides that specifically bind to the sortilin receptor. By continuing to use our service, you agree to our use of cookies. is a pharmaceutical company. 9 million and US. com uses cookies on this site. Amendment Withdraws the Condition to File HFS Report to the FDA to Access the US$20 Million Second Tranche. This news release constitutes a “designated news release” for the purposes of the Company’s. com uses cookies on this site. L. 's motion for leave to commence. We currently market prescription products for people with HIV in the United States. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies announced today that it will report its financial results for the second quarter of fiscal 2021 ended May 31, 2021 on Wednesday. MONTREAL, Feb. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. com uses cookies on this site. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic. (2022-10-26 | TSX:TH) Theratechnologies Reports Data Showing High Expression of Sortilin (SORT1) in Multiple Solid Tumors from Tissue Microarrays Stockhouse. com 10/16/2023. Theratechnologies (TH) has taken home a 2021 ADRIQ Innovation Award in the Life Sciences category. (TH. MONTREAL, July 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Further. Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights. 68 to a day high of $1. 2 million. Stockhouse. Theratechnologies (TH) has submitted a supplemental biologics license application (sBLA) to the U. MONTREAL, Jan. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that President and CEO, Paul Lévesque has issued an open letter to. Stockhouse. " The 12-month stock price forecast is $18. ET. TO) on CEO. B2Gold Declares Fourth Quarter 2023 Dividend. Browse posts by Sector and Subsector. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on. TH1902 is currently Theratechnologies’ lead investigational PDC candidate for the treatment of cancer derived from its SORT1+ Technology™. - TH1902 Phase 1 basket trial proceeding as planned. Investor Relations. 28, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH, Forum) noted that its Q1 2022 consolidated sales grew 20%, supported by 35% growth in sales of EGRIFTA SV formulation. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. a biopharmaceutical company focused on the development and commercialization of innovative therapies, today initiated enrollment of patients in the basket portion of the first-in-human study of TH1902, Theratechnologies’ investigational lead peptide drug conjugate (PDC) for the treatment of sortilin-expressing. The Canadian company develops peptide sequences to treat endocrine and metabolic conditions such as growth hormone deficiencies. Whether TH1902 impacts the chemoresistance phenotype of human triple-negative breast CSC. T. Theratechnologies' (TH) Senior Vice President and Chief Medical Officer Dr. The Company currently commercializes two products in the field of HIV. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650WELCOME TO SEDAR+ File, disclose and search for issuer information in Canada’s capital markets Search SEDAR+ All public disclosure documents Reporting Issuers List Filing organizations from all jurisdictions Disciplined List People and companies under disciplinary action Cease Trade Orders People and companies restricted from trading securities Sign. Conjugating the short peptide with various anti-cancer agents allows for. A live webcast of Dr. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that new data featuring its investigational sortilin 1 (SORT1)-targeting peptide-drug conjugate technology will be presented in three posters. Find the latest Theratechnologies Inc. 12, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies Inc (Theratechnologies) is a biopharmaceutical company that focuses on the discovery and development of drugs for people with orphan medical conditions. 3089 Background: SORT1 is expressed in a variety of tumors when compared to most healthy tissue. Theratechnologies is currently developing a platform of proprietary peptides called SORT1+ Technology TM for cancer drug development targeting SORT1 receptors. 15, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Wainwright NASH Investor Conference. (2021-03-20 | TSX:TH) Theratechnologies Announces New Data Demonstrating Tesamorelin's Positive Effect on Immune Response Linked to Liver Inflammation. (2022-07-27 | TSX:TH) Theratechnologies Announces Closing of Funding of $40 Million Under the Terms of its Credit Agreement Stockhouse. TH | Complete Theratechnologies Inc. Overview Stock Screener Earnings Calendar Sectors Nasdaq | THTX U. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that all five of the U. Stockhouse. Microsoft (NDAQ:MSFT) will expand its presence in Quebec with new computing capacity and AI and. TH1902 combines Theratechnologies’ proprietary peptide to. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its first quarter 2023 ended February 28, on Wednesday, April 12. 23 to a day high of $1. communications@theratech. It's a different kind of fat that may require a different type of treatment. WELCOME TO SEDAR+ File, disclose and search for issuer information in Canada’s capital markets Search SEDAR+ All public disclosure documents Reporting Issuers List Filing organizations from all jurisdictions Disciplined List People and companies under disciplinary action Cease Trade Orders People and companies restricted from trading securities Sign. [at noodls] - Montreal, Canada - April 17, 2015 - Theratechnologies Inc. 1. org. “This is yet another major achievement for our oncology program. Microsoft to invest $500M in Quebec AI economy. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced receipt of a notification letter (the “Notification Letter. Theratechnologies Inc. FY2022 revenue. (TH. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic.